Abstract:Background and objectives: Coronary artery bypass grafting (CABG) is the gold standard therapy for unprotected left main coronary artery (ULMCA) stenosis in coronary atherosclerosis. However, ULMCA stenosis has recently been successfully treated with drug-eluting stents. The present study aims to compare the safety and efficacy of CABG versus rapamycin-eluting stents for ULMCA stenosis in older adult patients with degenerative coronary atherosclerosis.Methods: The proposed prospective, non-randomized, controlled trial will include 224 older adult patients with degenerative coronary atherosclerosis with ULMCA stenosis being treated at Taihe Hospital (Affiliated Hospital of Hubei University of Medicine) and Renmin Hospital Affiliated to Hubei University of Medicine, China. Patients will be divided into two groups in accordance with each patient’s treatment choice and indications (n = 112/group): the stent group will receive rapamycin-eluting stents, while the CABG group will undergo CABG. All patients will be followed up at 9, 12, 24, and 36 months postoperatively.Outcome measures and preliminary results: The primary outcome measure will be the rate of repeat revascularizations in the target lesion at 36 months postoperatively. The secondary outcome measures will be the rates of repeat revascularizations in the target lesion at 9, 12, and 24 months postoperatively, the rate of restenosis, mortality, causes of death, and survival at 9, 12, 24, and 36 months postoperatively, and the angiographic appearance of the diseased vessels preoperatively and at 9, 12, 24, and 36 months postoperatively. The safety indicator will be the incidence of major adverse cardiac and cerebrovascular events at 9, 12, 24, and 36 months postoperatively. Pilot study results showed that the stent group (n = 48) had a significantly reduced waiting time for surgery, hospitalization time, and rate of complete revascularizations in the target lesion compared with the CABG group (n = 38) (P < 0.05). At 6 months postoperatively, there were no significant differences between the two groups in mortality, and incidences of myocardial infarction, repeat revascularizations in the target lesion, and cardiovascular events.Discussion: The results of this study will indicate the medium- and long-term efficacy and safety of rapamycin-eluting stents versus CABG in older adult patients with ULMCA stenosis.Ethics and dissemination: This study was approved by Medical Ethics Committee, Taihe Hospital (approval No. TH0058X), and Shiyan Renmin Hospital (approval No. RM011X), China in July 2017. This study protocol will be performed in strict accordance with the Declaration of Helsinki. Written informed consent will be obtained from each patient. The study protocol was designed in January 2018. Patient recruitment will begin in August 2018 and end in August 2019. Data analysis will begin in October 2022. The study will end in December 2022. Results will be disseminated through presentations at scientific meetings and/or by publication in a peer-reviewed journal.Trial registration: This trial was registered with the Chinese Clinical Trial Registry (registration number: ChiCTR1800016413). Protocol version: 1.0.

Rapamycin to Prevent Artery Restenosis after Stent Implantation:An Intravascular Ultrasound Study

Oral Rapamycin Prevents Artery Restenosis after Stent Implantation by Inhibiting Mammalian Target of Rapamycin ( Mtor )

Experimental Study of Stent-Based Delivery of Rapamycin and Tirofiban on Preventing In-Stent Thrombosis and Restenosis

Pretreatment with Intraluminal Rapamycin Nanoparticle Perfusion Inhibits Neointimal Hyperplasia in a Rabbit Vein Graft Model

Oral Rapamycin Attenuates Inflammation and Enhances Stability of Atherosclerotic Plaques in Rabbits Independent of Serum Lipid Levels.

Clinical Study of the Use of Rapamycin Eluting Etent

Effect of Rapamycin Eluting Stent for Inhibition of Neointimal Hyperplasia in Diabetic Porcine Model

Different released rapamycin eluting stents to reduce in-stent neointimal hyperplasia in a porcine coronary model

The Study of Rapamycin Nanofibrous Membrane for Preventing Arteriovenous Fistula Stenosis

Safety and Efficacy of Rapamycin-Eluting Vertebral Stents in Patients With Symptomatic Extracranial Vertebral Artery Stenosis

The Study of Rapamycin-Eluting Polymer-Coated Stents to Prevent Restenosis in the Porcine Coronary Injury Model

Effects of stent-based rapamycin-batroxobin on neointimal formation in a porcine coronary model

A cell membrane like biomimetic drug-eluting coronary stent

Effect Of Recombinant Human Sdf-1a On Re-Endothelialization After Sirolimus-Eluting Stent Implantation In Rabbit Aorta Abdominalis

A TEMPOL and rapamycin loaded nanofiber-covered stent favors endothelialization and mitigates neointimal hyperplasia and local inflammation

The effect of sirolimus-eluting stent implantation on re-endothelialization: a comparative study with bare-metal stent implantation in rabbits

Lactic-co-glycolic Acid Polymer with Rapamycin Coated Stent Reduces Neo-Intimal Formation in a Porcine Coronary Model

Single-Dose Treatment with Rapamycin Preserves Post-Ischemic Cardiac Function through Attenuation of Fibrosis and Inflammation in Diabetic Rabbit

[Pretreatment of Isolated Vein with Rapamycin Nanoparticles Inhibits Vein Graft Stenosis in Rabbits].

Rapamycin-eluting stents for unprotected left main coronary artery stenosis in older adult patients with coronary atherosclerosis: study protocol for a prospective, non-randomized, controlled trial and preliminary results

The Effects and Mechanisms of the Rapamycin-eluting Stent in Urethral Stricture Prevention in Rabbits